Form 8-K - Current report:
SEC Accession No. 0001689813-22-000005
Filing Date
2022-01-07
Accepted
2022-01-07 16:37:36
Documents
14
Period of Report
2022-01-04
Items
Item 7.01: Regulation FD Disclosure
Item 8.01: Other Events
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K bhvn-20220104.htm   iXBRL 8-K 35493
2 EX-99.1 a2022januarybhvnpfeclosing.htm EX-99.1 27498
6 GRAPHIC image.jpg GRAPHIC 441588
  Complete submission text file 0001689813-22-000005.txt   815886

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT bhvn-20220104.xsd EX-101.SCH 1920
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT bhvn-20220104_lab.xml EX-101.LAB 23800
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT bhvn-20220104_pre.xml EX-101.PRE 12508
8 EXTRACTED XBRL INSTANCE DOCUMENT bhvn-20220104_htm.xml XML 10525
Mailing Address 215 CHURCH STREET NEW HAVEN CT 06510
Business Address 215 CHURCH STREET NEW HAVEN CT 06510 203-404-0410
Biohaven Pharmaceutical Holding Co Ltd. (Filer) CIK: 0001689813 (see all company filings)

EIN.: 000000000 | State of Incorp.: D8 | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-38080 | Film No.: 22518589
SIC: 2834 Pharmaceutical Preparations